Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients. This article is protected by copyright. All rights reserved.